Novavax, Inc. (NVAX)' Phase I RSV Vaccine Data Published in Vaccine
12/7/2012 9:40:12 AM
ROCKVILLE, Md., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that the journal Vaccine has published the company's data from its 2011 Phase I clinical trial of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate. The paper was authored by a team of researchers and clinicians at Novavax and Dr. Pedro Piedra of Baylor College of Medicine. Findings from the trial were announced in October 2011 and presented in September 2012 by Novavax at the Respiratory Virus Symposium (RSV 2012) meeting in Santa Fe, New Mexico. The paper is currently available at www.novavax.com under Publications & Presentations/Publications and is expected to be published in the print edition shortly.